<DOC>
	<DOCNO>NCT00436774</DOCNO>
	<brief_summary>RATIONALE : Treatment pediatric extracranial germ cell tumor may cause side effect secondary cancer later life . A study evaluate patient receive combination chemotherapy surgery may help doctor understand side effect secondary cancer occur later life . PURPOSE : This study look treatment outcome quality life patient pediatric extracranial germ cell tumor previously treat clinical trial CCLG-GC-1979-01 CCLG-GC-1989-01 .</brief_summary>
	<brief_title>Treatment Outcome Quality Life Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated Clinical Trial CCLG-GC-1979-01 CCLG-GC-1989-01</brief_title>
	<detailed_description>OBJECTIVES : - Determine late effect treatment quality-of-life patient germ cell tumor ( GCT ) previously treat clinical trial CCLG-GC-1979-01 CCLG-GC-1989-01 . - Evaluate late effect carboplatin , etoposide , bleomycin patient treat clinical trial CCLG-GC-1989-01 . - Determine toxicity bleomycin combination either cisplatin vinblastine , etoposide cisplatin , carboplatin etoposide patient treat clinical trial CCLG-GC-1979-01 . - Evaluate tumor-associated/surgical morbidity ( bladder , bowel , low limb function ) patient malignant sacrococcygeal tumor treat clinical trial . - Evaluate tumor-associated/surgical morbidity ( sexual function/fertility ) patient malignant gonadal pelvic GCTs . - Evaluate tumor-associated/surgical morbidity ( respiratory function ) patient thoracic GCTs . - Develop methodology recommendation prospective late evaluation patient treated future extracranial GCT clinical trial include study . - Inform clinician late effect treatment malignant GCTs advise long-term care patient require . OUTLINE : This cohort , multicenter study . Patients complete questionnaire ototoxicity , bladder bowel dysfunction , sexual function fertility appropriate . They also complete health-related quality-of-life questionnaire 20 minute . Treating physician complete lower-limb neurologic dysfunction questionnaire . Data myelodysplasia , second malignancy , ototoxicity , nephrotoxicity , pulmonary toxicity assessment collect patient 's treating physician . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously enrol 1 follow United Kingdom Children 's Cancer Study Group ( UKCCSG ) clinical trial treatment extracranial germ cell tumor : CCLGGC198901 CCLGGC197901 Received bleomycin cisplatin therapy At least 5 year since completion therapy clinical trial Attending contact UKCCSG center Patients treat sacrococcygeal teratoma discharge followup eligible No recurrent progressive disease PATIENT CHARACTERISTICS : No patient deem unsuitable study treat clinician PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>long-term effect secondary cancer therapy child</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>gastrointestinal complication</keyword>
	<keyword>pulmonary complication</keyword>
	<keyword>sexual dysfunction</keyword>
	<keyword>infertility</keyword>
	<keyword>urinary complication</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood teratoma</keyword>
</DOC>